Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
12 December 2020 |
Main ID: |
NCT03179137 |
Date of registration:
|
30/05/2017 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
Mitochondrial Bioenergetics and Role in Cellular Damage in Ischemic Myocardium
|
Scientific title:
|
Pathophysiological Mechanisms Elicited by Ischemia and Metabolic Co-morbidities in Myocardium of Patients With Coronary Artery Disease |
Date of first enrolment:
|
October 1, 2016 |
Target sample size:
|
80 |
Recruitment status: |
Active, not recruiting |
URL:
|
https://clinicaltrials.gov/show/NCT03179137 |
Study type:
|
Observational |
Study design:
|
|
Phase:
|
|
|
Countries of recruitment
|
Croatia
| | | | | | | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Coronary artery disease
- Indication for coronary artery bypass grafting surgery
Exclusion Criteria:
- Emergency patients
- Patients with LV ejection fraction (LVEF) below 30%
- Patients with severe renal, hepatic or pulmonary disease
Age minimum:
50 Years
Age maximum:
85 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Coronary Artery Disease
|
Mitochondrial Metabolism Disorders
|
Diabetes Mellitus
|
Intervention(s)
|
Other: Standard therapy
|
Primary Outcome(s)
|
Myocardial production of reactive oxygen species
[Time Frame: 2016-2020]
|
Mitochondrial oxygen consumption (rate of oxygen consumption per milligram of left ventricular tissue)
[Time Frame: 2016-2020]
|
Secondary Outcome(s)
|
Anti-cardiolipin antibodies in the blood of patients with symptoms of cardiac ischemia
[Time Frame: 2016-2020]
|
Secondary ID(s)
|
2181-198-03
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|